Acura Pharmaceuticals, INC: directors' dealings · United States · SEC (Form 4)

About Acura Pharmaceuticals, INC

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) is a U.S.-based specialty pharmaceutical company focused on the research, development, and commercialization of products designed to reduce medication abuse and misuse. The company is headquartered in Palatine, Illinois, United States, and its recent SEC filing data confirms a Palatine operating address together with a NASDAQ listing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/786947/000110465926004048/0001104659-26-004048-index.htm)) Acura’s business model has historically been built around proprietary formulation technologies rather than discovery-stage drug development. The core idea is to apply abuse-deterrent engineering to well-known active ingredients so that products remain therapeutically effective while becoming harder to crush, snort, inject, or otherwise misuse. The company highlights three main technology platforms: AVERSION®, IMPEDE®, and LIMITX™. This gives Acura a focused niche in specialty pharma, with differentiation coming from formulation science and intellectual property rather than broad-scale primary care promotion. ([acurapharm.com](https://acurapharm.com/technology-platforms/)) On the commercial side, Acura’s portfolio has centered on abuse-deterrent and misuse-resistant products. Its best-known marketed product is NEXAFED®, an immediate-release pseudoephedrine HCl tablet using IMPEDE® technology to make extraction of pseudoephedrine more difficult for illicit methamphetamine production. The company also markets NEXAFED Sinus Pressure + Pain, a pseudoephedrine/acetaminophen combination, and has historically developed OXAYDO®, an oxycodone product using AVERSION® technology. Acura’s stated operating model is asset-light: it relies on third-party manufacturing and licensing partnerships rather than a large physician-focused sales force. ([acurapharm.com](https://acurapharm.com/technology-platforms/)) From an equity research perspective, Acura’s competitive position is that of a small, highly specialized player addressing a narrow but socially relevant segment of the pharmaceutical market. The abuse-deterrence theme can provide regulatory and branding advantages, but it also means the company is concentrated in a limited number of products and partner relationships. The company’s commercial footprint is primarily North American for NEXAFED through licensing arrangements, while its broader pipeline has been framed around extending the same technology platforms to other abusable therapeutic categories. ([acurapharm.com](https://acurapharm.com/our-business/about-acura/)) Recent developments are dominated by balance-sheet and filing risk. A 2026 SEC-related notice indicates Acura delayed filing its Form 10-Q for the quarter ended March 31, 2026 because of liquidity constraints and its ability to meet day-to-day operating obligations. The broader SEC trail also shows Form 4 insider-transaction activity, underscoring that the stock remains on the radar of event-driven and microcap investors, albeit in a high-risk context. In short, Acura is best viewed as a speculative Health & Pharma name on NASDAQ in the United States, with valuation heavily dependent on financing capacity, licensing economics, and the protection of its intellectual property. ([stocktitan.net](https://www.stocktitan.net/sec-filings/ACUR/nt-10-q-acura-pharmaceuticals-inc-sec-filing-1398524acd59.html?utm_source=openai))